NeXT Personal, a highly sensitive molecular residual disease test, is a strong predictor of outcomes in patients with stage II-IIIb, EGFR-mutated non-small cell lung cancer receiving neoadjuvant therapy, according to data from NeoADAURA phase III clinical trial run by AstraZeneca.
Look at where our understanding of cancer was two, five, 10, 15, 20, or more years ago and then consider what has happened over the past two decades. We finally realized how more complex the problem of cancer is—more than any of us imagined.
